{
    "xml": "<topic id=\"PHP7860\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/co-cyprindiol\" basename=\"co-cyprindiol\" title=\"CO-CYPRINDIOL\">\n<title>CO-CYPRINDIOL</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_638\" namespace=\"/interactions/list-of-drug-interactions/oestrogens/ethinylestradiol\">Ethinylestradiol</xref>\n</p>\n<data name=\"vtmid\">18036911000001101</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_677939183\" title=\"Anti-androgens\">Anti-androgens</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n</body>\n<topic id=\"PHP64273\" outputclass=\"indicationsAndDose\" rev=\"1.21\" parent=\"/drugs/co-cyprindiol\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Moderate to severe acne in women of child-bearing age refractory to topical therapy or oral antibacterials</p>\n<p outputclass=\"therapeuticIndication\">Moderately severe hirsutism</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Females of childbearing potential</p>\n<p>1&#8239;tablet daily for 21 days, to be started on day 1 of menstrual cycle; subsequent courses repeated after a 7-day interval (during which withdrawal bleeding occurs), time to symptom remission, at least 3 months; review need for treatment regularly.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64321\" outputclass=\"contraindications\" rev=\"1.12\" parent=\"/drugs/co-cyprindiol\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Acute porphyria</ph>; <ph outputclass=\"contraindication\">gallstones</ph>; <ph outputclass=\"contraindication\">heart disease associated with pulmonary hypertension or risk of embolus</ph>; <ph outputclass=\"contraindication\">history during pregnancy of cholestatic jaundice</ph>; <ph outputclass=\"contraindication\">history during pregnancy of chorea</ph>; <ph outputclass=\"contraindication\">history during pregnancy of pemphigoid gestationis</ph>; <ph outputclass=\"contraindication\">history during pregnancy of pruritus</ph>; <ph outputclass=\"contraindication\">history of breast cancer but can be used after 5 years if no evidence of disease and non-hormonal methods unacceptable</ph>; <ph outputclass=\"contraindication\">history of haemolytic uraemic syndrome</ph>; <ph outputclass=\"contraindication\">migraine with aura</ph>; <ph outputclass=\"contraindication\">personal history of venous or arterial thrombosis</ph>; <ph outputclass=\"contraindication\">sclerosing treatment for varicose veins</ph>; <ph outputclass=\"contraindication\">severe or multiple risk factors for arterial disease or for venous thromboembolism</ph>; <ph outputclass=\"contraindication\">systemic lupus erythematosus with (or unknown) antiphospholipid antibodies</ph>; <ph outputclass=\"contraindication\">transient cerebral ischaemic attacks without headaches</ph>; <ph outputclass=\"contraindication\">undiagnosed vaginal bleeding</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64342\" outputclass=\"cautions\" rev=\"1.20\" parent=\"/drugs/co-cyprindiol\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)&#8212;seek specialist advice</ph>; <ph outputclass=\"caution\">arterial disease</ph>; <ph outputclass=\"caution\">gene mutations associated with breast cancer (e.g. BRCA 1)</ph>; <ph outputclass=\"caution\">history of severe depression especially if induced by hormonal contraceptive</ph>; <ph outputclass=\"caution\">hyperprolactinaemia&#8212;seek specialist advice</ph>; <ph outputclass=\"caution\">inflammatory bowel disease including Crohn's disease</ph>; <ph outputclass=\"caution\">migraine</ph>; <ph outputclass=\"caution\">personal or family history of hypertriglyceridaemia (increased risk of pancreatitis)</ph>; <ph outputclass=\"caution\">risk factors for venous thromboembolism</ph>; <ph outputclass=\"caution\">sickle-cell disease</ph>; <ph outputclass=\"caution\">undiagnosed breast mass</ph>\n</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Venous thromboembolism</p>\n<p>There is an increased risk of venous thromboembolism in women taking co-cyprindiol, particularly during the first year of use. The incidence of venous thromboembolism is 1.5&#8211;2 times higher in women using co-cyprindiol than in women using combined oral contraceptives containing levonorgestrel, but the risk may be similar to that associated with use of combined oral contraceptives containing third generation progestogens (desogestrel and gestodene) or drospirenone. Women requiring co-cyprindiol may have an inherently increased risk of cardiovascular disease.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64262\" outputclass=\"interactions\" rev=\"1.9\" parent=\"/drugs/co-cyprindiol\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (oestrogens).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64228\" outputclass=\"sideEffects\" rev=\"1.11\" parent=\"/drugs/co-cyprindiol\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Rarely gallstones</ph>; <ph outputclass=\"sideEffect\">systemic lupus erythematosus</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"veryRare\">\n<p outputclass=\"title\">Very rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Photosensitivity</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal cramps</ph>; <ph outputclass=\"sideEffect\">absence of withdrawal bleeding</ph>; <ph outputclass=\"sideEffect\">amenorrhoea after discontinuation</ph>; <ph outputclass=\"sideEffect\">breast enlargement</ph>; <ph outputclass=\"sideEffect\">breast secretion</ph>; <ph outputclass=\"sideEffect\">breast tenderness</ph>; <ph outputclass=\"sideEffect\">cervical erosion</ph>; <ph outputclass=\"sideEffect\">changes in libido</ph>; <ph outputclass=\"sideEffect\">changes in lipid metabolism</ph>; <ph outputclass=\"sideEffect\">changes in vaginal discharge</ph>; <ph outputclass=\"sideEffect\">chloasma</ph>; <ph outputclass=\"sideEffect\">chorea</ph>; <ph outputclass=\"sideEffect\">contact lenses may irritate</ph>; <ph outputclass=\"sideEffect\">depression</ph>; <ph outputclass=\"sideEffect\">fluid retention</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hepatic tumours</ph>; <ph outputclass=\"sideEffect\">hypertension</ph>; <ph outputclass=\"sideEffect\">irritability</ph>; <ph outputclass=\"sideEffect\">leg cramps</ph>; <ph outputclass=\"sideEffect\">liver impairment</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">nervousness</ph>; <ph outputclass=\"sideEffect\">reduced menstrual loss</ph>; <ph outputclass=\"sideEffect\">skin reactions</ph>; <ph outputclass=\"sideEffect\">thrombosis (more common when factor V Leiden present or in blood groups A, B, and AB</ph>; <ph outputclass=\"sideEffect\">visual disturbances</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>; <ph outputclass=\"sideEffect\">&#8216;spotting&#8217; in early cycles</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64254\" outputclass=\"pregnancy\" parent=\"/drugs/co-cyprindiol\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;risk of feminisation of male fetus with cyproterone.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64356\" outputclass=\"breastFeeding\" parent=\"/drugs/co-cyprindiol\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid; possibility of anti-androgen effects in neonate with cyproterone.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP64284\" outputclass=\"hepaticImpairment\" parent=\"/drugs/co-cyprindiol\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin-Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), and liver tumours.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61665\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.8\" parent=\"/drugs/co-cyprindiol\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>A mixture of cyproterone acetate and ethinylestradiol in the mass proportions 2000 parts to 35 parts, respectively.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP7860-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/co-cyprindiol\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75981\" title=\"Tablet\" namespace=\"/drugs/co-cyprindiol/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78083\" namespace=\"/treatment-summaries/scalp-and-hair-conditions\" title=\"Scalp and hair conditions\" count=\"1\" rel=\"backlink\">Scalp and hair conditions</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78307\" namespace=\"/treatment-summaries/rosacea-and-acne\" title=\"Rosacea and Acne\" count=\"3\" rel=\"backlink\">Rosacea and Acne</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_638\" namespace=\"/interactions/list-of-drug-interactions/oestrogens/ethinylestradiol\" title=\"Ethinylestradiol\" count=\"1\" rel=\"link\">Ethinylestradiol</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75981\" namespace=\"/drugs/co-cyprindiol/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP7860",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/co-cyprindiol",
    "basename": "co-cyprindiol",
    "title": "CO-CYPRINDIOL",
    "interactants": [
        {
            "id": "bnf_int_638",
            "label": "Ethinylestradiol"
        }
    ],
    "vtmid": "18036911000001101",
    "drugClassification": [
        "Anti-androgens"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Moderate to severe acne in women of child-bearing age refractory to topical therapy or oral antibacterials",
                        "html": "Moderate to severe acne in women of child-bearing age refractory to topical therapy or oral antibacterials"
                    },
                    {
                        "textContent": "Moderately severe hirsutism",
                        "html": "Moderately severe hirsutism"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "1 tablet daily for 21 days, to be started on day 1 of menstrual cycle; subsequent courses repeated after a 7-day interval (during which withdrawal bleeding occurs), time to symptom remission, at least 3 months; review need for treatment regularly.",
                        "html": "<p>1&#8239;tablet daily for 21 days, to be started on day 1 of menstrual cycle; subsequent courses repeated after a 7-day interval (during which withdrawal bleeding occurs), time to symptom remission, at least 3 months; review need for treatment regularly.</p>",
                        "ageGroup": "females of childbearing potential"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Acute porphyria",
                "html": "Acute porphyria"
            },
            {
                "type": "contraindications",
                "textContent": "gallstones",
                "html": "gallstones"
            },
            {
                "type": "contraindications",
                "textContent": "heart disease associated with pulmonary hypertension or risk of embolus",
                "html": "heart disease associated with pulmonary hypertension or risk of embolus"
            },
            {
                "type": "contraindications",
                "textContent": "history during pregnancy of cholestatic jaundice",
                "html": "history during pregnancy of cholestatic jaundice"
            },
            {
                "type": "contraindications",
                "textContent": "history during pregnancy of chorea",
                "html": "history during pregnancy of chorea"
            },
            {
                "type": "contraindications",
                "textContent": "history during pregnancy of pemphigoid gestationis",
                "html": "history during pregnancy of pemphigoid gestationis"
            },
            {
                "type": "contraindications",
                "textContent": "history during pregnancy of pruritus",
                "html": "history during pregnancy of pruritus"
            },
            {
                "type": "contraindications",
                "textContent": "history of breast cancer but can be used after 5 years if no evidence of disease and non-hormonal methods unacceptable",
                "html": "history of breast cancer but can be used after 5 years if no evidence of disease and non-hormonal methods unacceptable"
            },
            {
                "type": "contraindications",
                "textContent": "history of haemolytic uraemic syndrome",
                "html": "history of haemolytic uraemic syndrome"
            },
            {
                "type": "contraindications",
                "textContent": "migraine with aura",
                "html": "migraine with aura"
            },
            {
                "type": "contraindications",
                "textContent": "personal history of venous or arterial thrombosis",
                "html": "personal history of venous or arterial thrombosis"
            },
            {
                "type": "contraindications",
                "textContent": "sclerosing treatment for varicose veins",
                "html": "sclerosing treatment for varicose veins"
            },
            {
                "type": "contraindications",
                "textContent": "severe or multiple risk factors for arterial disease or for venous thromboembolism",
                "html": "severe or multiple risk factors for arterial disease or for venous thromboembolism"
            },
            {
                "type": "contraindications",
                "textContent": "systemic lupus erythematosus with (or unknown) antiphospholipid antibodies",
                "html": "systemic lupus erythematosus with (or unknown) antiphospholipid antibodies"
            },
            {
                "type": "contraindications",
                "textContent": "transient cerebral ischaemic attacks without headaches",
                "html": "transient cerebral ischaemic attacks without headaches"
            },
            {
                "type": "contraindications",
                "textContent": "undiagnosed vaginal bleeding",
                "html": "undiagnosed vaginal bleeding"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)&#8212;seek specialist advice",
                "html": "Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)&#8212;seek specialist advice"
            },
            {
                "type": "cautions",
                "textContent": "arterial disease",
                "html": "arterial disease"
            },
            {
                "type": "cautions",
                "textContent": "gene mutations associated with breast cancer (e.g. BRCA 1)",
                "html": "gene mutations associated with breast cancer (e.g. BRCA 1)"
            },
            {
                "type": "cautions",
                "textContent": "history of severe depression especially if induced by hormonal contraceptive",
                "html": "history of severe depression especially if induced by hormonal contraceptive"
            },
            {
                "type": "cautions",
                "textContent": "hyperprolactinaemia&#8212;seek specialist advice",
                "html": "hyperprolactinaemia&#8212;seek specialist advice"
            },
            {
                "type": "cautions",
                "textContent": "inflammatory bowel disease including Crohn's disease",
                "html": "inflammatory bowel disease including Crohn's disease"
            },
            {
                "type": "cautions",
                "textContent": "migraine",
                "html": "migraine"
            },
            {
                "type": "cautions",
                "textContent": "personal or family history of hypertriglyceridaemia (increased risk of pancreatitis)",
                "html": "personal or family history of hypertriglyceridaemia (increased risk of pancreatitis)"
            },
            {
                "type": "cautions",
                "textContent": "risk factors for venous thromboembolism",
                "html": "risk factors for venous thromboembolism"
            },
            {
                "type": "cautions",
                "textContent": "sickle-cell disease",
                "html": "sickle-cell disease"
            },
            {
                "type": "cautions",
                "textContent": "undiagnosed breast mass",
                "html": "undiagnosed breast mass"
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Venous thromboembolism",
                "textContent": "There is an increased risk of venous thromboembolism in women taking co-cyprindiol, particularly during the first year of use. The incidence of venous thromboembolism is 1.5&#8211;2 times higher in women using co-cyprindiol than in women using combined oral contraceptives containing levonorgestrel, but the risk may be similar to that associated with use of combined oral contraceptives containing third generation progestogens (desogestrel and gestodene) or drospirenone. Women requiring co-cyprindiol may have an inherently increased risk of cardiovascular disease.",
                "html": "<p>There is an increased risk of venous thromboembolism in women taking co-cyprindiol, particularly during the first year of use. The incidence of venous thromboembolism is 1.5&#8211;2 times higher in women using co-cyprindiol than in women using combined oral contraceptives containing levonorgestrel, but the risk may be similar to that associated with use of combined oral contraceptives containing third generation progestogens (desogestrel and gestodene) or drospirenone. Women requiring co-cyprindiol may have an inherently increased risk of cardiovascular disease.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (oestrogens).",
                "html": "<p>Appendix 1 (oestrogens).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Rarely gallstones",
                        "html": "Rarely gallstones",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "systemic lupus erythematosus",
                        "html": "systemic lupus erythematosus",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "veryRare": [
                    {
                        "type": "veryRare",
                        "textContent": "Photosensitivity",
                        "html": "Photosensitivity",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Abdominal cramps",
                        "html": "Abdominal cramps",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "absence of withdrawal bleeding",
                        "html": "absence of withdrawal bleeding",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "amenorrhoea after discontinuation",
                        "html": "amenorrhoea after discontinuation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "breast enlargement",
                        "html": "breast enlargement",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "breast secretion",
                        "html": "breast secretion",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "breast tenderness",
                        "html": "breast tenderness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "cervical erosion",
                        "html": "cervical erosion",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "changes in libido",
                        "html": "changes in libido",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "changes in lipid metabolism",
                        "html": "changes in lipid metabolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "changes in vaginal discharge",
                        "html": "changes in vaginal discharge",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "chloasma",
                        "html": "chloasma",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "chorea",
                        "html": "chorea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "contact lenses may irritate",
                        "html": "contact lenses may irritate",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "depression",
                        "html": "depression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "fluid retention",
                        "html": "fluid retention",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hepatic tumours",
                        "html": "hepatic tumours",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypertension",
                        "html": "hypertension",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "irritability",
                        "html": "irritability",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "leg cramps",
                        "html": "leg cramps",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "liver impairment",
                        "html": "liver impairment",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nervousness",
                        "html": "nervousness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "reduced menstrual loss",
                        "html": "reduced menstrual loss",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "skin reactions",
                        "html": "skin reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thrombosis (more common when factor V Leiden present or in blood groups A, B, and AB",
                        "html": "thrombosis (more common when factor V Leiden present or in blood groups A, B, and AB",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "visual disturbances",
                        "html": "visual disturbances",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "&#8216;spotting&#8217; in early cycles",
                        "html": "&#8216;spotting&#8217; in early cycles",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;risk of feminisation of male fetus with cyproterone.",
                "html": "<p>Avoid&#8212;risk of feminisation of male fetus with cyproterone.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid; possibility of anti-androgen effects in neonate with cyproterone.",
                "html": "<p>Manufacturer advises avoid; possibility of anti-androgen effects in neonate with cyproterone.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin-Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), and liver tumours.",
                "html": "<p>Avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin-Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), and liver tumours.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "A mixture of cyproterone acetate and ethinylestradiol in the mass proportions 2000 parts to 35 parts, respectively.",
                "html": "<p>A mixture of cyproterone acetate and ethinylestradiol in the mass proportions 2000 parts to 35 parts, respectively.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75981",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78083",
                "label": "Scalp and hair conditions",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78307",
                "label": "Rosacea and Acne",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_638",
                "label": "Ethinylestradiol",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75981",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}